MDxHealth SAMDXH
Price (close)
$0.58
Market cap
$55.5M
P/E
—
Revenue (FY)
$107.9M
Net income
-$33.5M
Dividend yield
—
1-year total return
-86.5%
Net margin
-31.1%
Revenue growth
19.8%
Debt / equity
—
What MDxHealth SA does.
company providing non-invasive, clinically actionable and cost-effective urologic solutions to improve patient care. Our core menu of
Prostate Test (“Exo mdx”), which we recently added through the acquisition of Exosome Diagnostics, provide personalized DNA
and RNA insights to both physicians and patients navigating the complexities of urologic disease and treatment options. Each of our cutting-edge
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $18.5M | $22.2M | $37.1M | $70.2M | $90.0M | $107.9M |
| Net income | -$28.7M | -$29.0M | -$44.0M | -$43.1M | -$38.1M | -$33.5M |
| Free cash flow | -$20.8M | -$23.4M | -$36.9M | -$24.2M | -$19.7M | -$3.3M |
More on MDXH.
- MDxHealth SA summary
- MDxHealth SA financial statements
- MDxHealth SA key metrics
- MDxHealth SA health scores and style box
- MDxHealth SA earnings
- MDxHealth SA dividends
- MDxHealth SA valuation
- MDxHealth SA ownership and insiders
- MDxHealth SA peers
Figures from MDxHealth SA's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.